BioCryst Pharmaceuticals
BCRX
BCRX
115 hedge funds and large institutions have $384M invested in BioCryst Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 27 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
2% less funds holding
Funds holding: 117 → 115 (-2)
32% less capital invested
Capital invested by funds: $568M → $384M (-$184M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Holders
115
Holding in Top 10
4
Calls
$6.27M
Puts
$2.01M
Top Buyers
| 1 | +$9.3M | |
| 2 | +$9.27M | |
| 3 | +$9.1M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.54M |
| 5 |
Millennium Management
New York
|
+$3.15M |
Top Sellers
| 1 | -$20M | |
| 2 | -$9.06M | |
| 3 | -$5.92M | |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$4.59M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.18M |